Literature DB >> 7743295

Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.

C P Speer1, O Gefeller, P Groneck, E Laufkötter, C Roll, L Hanssler, K Harms, E Herting, H Boenisch, J Windeler.   

Abstract

AIMS: To compare treatment regimens of two widely used natural surfactant preparations Curosurf and Survanta in respiratory distress syndrome (RDS).
METHODS: The effects of the two treatment regimens on gas exchange, ventilatory requirements, and 28 day outcome in infants with RDS were compared. Seventy five preterm infants (birth weight 700-1500 g) with RDS requiring artificial ventilation with an FIO2 of > or = 0.4, were randomly selected at 1-24 hours of age. One group received an initial dose of Curosurf (200 mg/kg); the other group Survanta (100 mg/kg). Patients who remained dependent on artificial ventilation with an FIO2 of > or = 0.3 received up to two additional doses of Curosurf (each of 100 mg/kg) after 12 and 24 hours or up to three additional doses of Survanta (each of 100 mg/kg) between six and 48 hours after the initial dose.
RESULTS: There was a rapid improvement in oxygenation and ventilatory requirements were reduced in both groups. However, infants treated with Curosurf had a higher arterial:alveolar oxygen tension ratio and required a lower peak inspiratory pressure and mean airway pressure at several time points within 24 hours of randomisation (p < 0.05-0.001). The incidences of pneumothorax in the Curosurf and Survanta groups were 6% and 12.5%, respectively; the corresponding figures for grades 3-4 intracerebral haemorrhage were 3% and 12.5%, respectively. Mortality was 3% in the Curosurf group and 12.5% in the Survanta group. However, these differences did not reach significance.
CONCLUSION: The Curosurf treatment regimen resulted in a more rapid improvement in oxygenation than Survanta and reduced ventilatory requirements up to 24 hours after start of treatment. This was associated with a trend towards reduced incidence of serious pulmonary and non-pulmonary complications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7743295      PMCID: PMC2528411          DOI: 10.1136/fn.72.1.f8

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  17 in total

Review 1.  Intention-to-treat analysis: implications for quantitative and qualitative research.

Authors:  D J Newell
Journal:  Int J Epidemiol       Date:  1992-10       Impact factor: 7.196

2.  Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm.

Authors:  L A Papile; J Burstein; R Burstein; H Koffler
Journal:  J Pediatr       Date:  1978-04       Impact factor: 4.406

Review 3.  Pulmonary surfactant therapy.

Authors:  A H Jobe
Journal:  N Engl J Med       Date:  1993-03-25       Impact factor: 91.245

4.  Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized trial.

Authors:  J Egberts; J P de Winter; G Sedin; M J de Kleine; U Broberger; F van Bel; T Curstedt; B Robertson
Journal:  Pediatrics       Date:  1993-12       Impact factor: 7.124

5.  Correlations between physical and physiological properties of various preparations of lung surfactant.

Authors:  K Nohara; P Berggren; T Curstedt; G Grossmann; R Nilsson; B Robertson
Journal:  Eur J Respir Dis       Date:  1986-11

6.  Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial).

Authors:  H L Halliday; W O Tarnow-Mordi; J D Corcoran; C C Patterson
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

7.  Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome.

Authors:  C P Speer; D Ruess; K Harms; E Herting; O Gefeller
Journal:  Pediatrics       Date:  1993-04       Impact factor: 7.124

8.  A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.

Authors:  J D Horbar; L L Wright; R F Soll; E C Wright; A A Fanaroff; S B Korones; S Shankaran; W Oh; B D Fletcher; C R Bauer
Journal:  J Pediatr       Date:  1993-11       Impact factor: 4.406

9.  Elastase-alpha 1-proteinase inhibitor: an early indicator of septicemia and bacterial meningitis in children.

Authors:  C P Speer; M Rethwilm; M Gahr
Journal:  J Pediatr       Date:  1987-11       Impact factor: 4.406

10.  Periventricular leucomalacia and neurodevelopmental outcome in preterm infants.

Authors:  C L Fawer; P Diebold; A Calame
Journal:  Arch Dis Child       Date:  1987-01       Impact factor: 3.791

View more
  35 in total

Review 1.  Current perspectives on the drug treatment of neonatal respiratory distress syndrome.

Authors:  D G Sweet; H L Halliday
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

2.  A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.

Authors:  H Walti; M Monset-Couchard
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

3.  The effects of surfactant on haemodynamics in hyaline membrane disease.

Authors:  J Skinner
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-03       Impact factor: 5.747

4.  Nasal masks or binasal prongs for delivering continuous positive airway pressure in preterm neonates-a randomised trial.

Authors:  Aparna Chandrasekaran; Anu Thukral; M Jeeva Sankar; Ramesh Agarwal; Vinod K Paul; Ashok K Deorari
Journal:  Eur J Pediatr       Date:  2017-01-13       Impact factor: 3.183

Review 5.  The role of surfactant and non-invasive mechanical ventilation in early management of respiratory distress syndrome in premature infants.

Authors:  Narayan Prabhu Iyer; Maroun Jean Mhanna
Journal:  World J Pediatr       Date:  2014-08-15       Impact factor: 2.764

Review 6.  Surfactant therapy: the current practice and the future trends.

Authors:  Khalid Altirkawi
Journal:  Sudan J Paediatr       Date:  2013

7.  Poractant Alfa Versus Beractant for Neonatal Respiratory Distress Syndrome: A Retrospective Cost Analysis.

Authors:  Sara Brown; Jeff Hurren; Heidi Sartori
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

Review 8.  Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future.

Authors:  Smeeta Sardesai; Manoj Biniwale; Fiona Wertheimer; Arlene Garingo; Rangasamy Ramanathan
Journal:  Pediatr Res       Date:  2016-10-05       Impact factor: 3.756

9.  Need to avoid bias in controlled trials.

Authors:  S Logan
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-09       Impact factor: 5.747

10.  The effects of antenatal corticosteroids and surfactant replacement on neonatal respiratory distress syndrome.

Authors:  Suada Heljić; Hajrija Maksić; Ismeta Kalkan; Belma Krdalić
Journal:  Bosn J Basic Med Sci       Date:  2009-08       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.